TY - JOUR
T1 - Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
AU - Marchand, Marie
AU - Van Baren, Nicolas
AU - Weynants, Patrick
AU - Brichard, Vincent
AU - Dréno, Brigitte
AU - Tessier, Marie Hélène
AU - Rankin, Elaine
AU - Parmiani, Giorgio
AU - Arienti, Flavio
AU - Humblet, Yves
AU - Bourlond, André
AU - Vanwijck, Romain
AU - Liénard, Danielle
AU - Beauduin, Marc
AU - Dietrich, Pierre Yves
AU - Russo, Vincenzo
AU - Kerger, Joseph
AU - Masucci, Giuseppe
AU - Jäger, Elke
AU - De Greve, Jacques
AU - Atzpodien, Jens
AU - Brasseur, Francis
AU - Coulie, Pierre G.
AU - Van Der Bruggen, Pierre
AU - Boon, Thierry
PY - 1999/1/18
Y1 - 1999/1/18
N2 - Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
AB - Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
UR - http://www.scopus.com/inward/record.url?scp=0033579934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033579934&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S
DO - 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S
M3 - Article
C2 - 9935203
AN - SCOPUS:0033579934
VL - 80
SP - 219
EP - 230
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 2
ER -